Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for Pacific Biosciences, revealing an average target of $3.64, a high estimate of $8.00, and a low estimate of $2.00. A decline of 57.92% from the prior average price target is evident in the current average.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light...